Amgen (AMGN) Receivables - Other (2013 - 2024)

Amgen has reported Receivables - Other for 8 years, with the latest figure at $521.0 million in Q4 2024.

• On a quarterly basis, Receivables - Other rose 3.78% year-over-year to $521.0 million in Q4 2024; TTM through Dec 2024 was $521.0 million, a 3.78% increase from a year earlier, with the FY2024 full-year figure at $521.0 million, up 3.78% from the prior year.
• Receivables - Other was $521.0 million for Q4 2024 at Amgen, up from $502.0 million in the prior quarter.
• The five-year high for Receivables - Other was $780.0 million in Q4 2021, with the low at $502.0 million in Q4 2023.
• Average Receivables - Other over 5 years is $617.2 million, with a median of $583.0 million recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Receivables - Other soared 33.79% in 2021, then slipped 28.29% in 2023.
• Over 5 years, Receivables - Other stood at $583.0 million in 2020, then jumped by 33.79% to $780.0 million in 2021, then declined by 10.26% to $700.0 million in 2022, then slipped by 28.29% to $502.0 million in 2023, then advanced by 3.78% to $521.0 million in 2024.
• The last three Receivables - Other figures came in at $521.0 million (Q4 2024), $502.0 million (Q4 2023), and $700.0 million (Q4 2022), per Business Quant data.